Key facts
- BrainEye’s last known valuation is $41.0M (Jul 2025).
- It has raised $5.3M; the latest was Later Stage VC ($5.3M) in Jul 2025.
- Notable investors include ANDHealth, XV Capital.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for BrainEye
- ·The full record, as it builds
Funding rounds
No funding rounds for BrainEye are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BrainEye
Developer of an eye movement tracking application designed to track neurological health using a smartphone. The company's brain health assessment technology offers an accessible and reliable tool for detecting brain abnormalities, enabling individuals to monitor and improve their brain health, thereby enhancing overall well-being and performance, while reducing the burden on healthcare systems.
- Sector
- Healthcare
- HQ
- Chippendale, Australia
- Founded
- 2014
- Employees
- 26
- Website
- braineye.com/
- Ownership
- Privately Held (backing)
BrainEye doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BrainEye shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BrainEye in its N-PORT filings yet. We sweep new filings monthly.